抄録
The direct reprogramming of somatic cells to produce induced pluripotent stem (iPS) cells represents a recent prominent advance in stem cell biology. iPS cells have strong potentials for regenerative therapy and innovation of the human inheritable disease models. Initially, human dermal fibroblasts were used to derive human iPS cells. However, recent studies have shown that other human somatic cells, such as keratinocyte stem cells, adipose stem cells, dental stem cells, neural stem cells, and hematopoietic stem/progenitor cells, can be used for this purpose. But it is difficult to obtain somatic stem cells. Terminally differentiated T cells can be easily obtained from peripheral blood and proliferated upon activation by plate-bound anti-CD3 monoclonal antibody and recombinant IL-2. Sendai virus (SeV) which is a negative-sense, single-stranded RNA virus that does not integrate into the host genome, was efficiently transfected into the activated T cells. In the present study, we show that the combination of activated T-cell cultivation and a temperature-sensitive mutated SeV that encodes human OCT3/4, SOX2, KLF4, and c-MYC allows the generation of human iPS cells easily, efficiently, and safely within 1 month. T cell-derived iPS cells are expected to be used in the clinical setting.
